Relationships between regulatory T cells and CD8+effector populations in patients with squamous cell carcinoma of the head and neck

被引:60
作者
Chikamatsu, Kazuaki [1 ]
Sakakura, Koichi
Whiteside, Theresa L.
Furuya, Nobuhiko
机构
[1] Gunma Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Maebashi, Gunma 3718511, Japan
[2] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA
[5] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2007年 / 29卷 / 02期
关键词
squamous cell carcinoma of the head and neck (SCCHN); Th1; Th2; Tc1; Tc2; CD4+CD25+regulatory T cells (Treg);
D O I
10.1002/hed.20490
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Homeostasis of circulating T cells Is regulated in complex ways that have not yet been well defined. The balance between type 1 and type 2 T-cell subsets in cancer patients is thought to modulate antitumor immunity. Meanwhile, CD4+CD25+ regulatory T cells (Treg), which are potent Inhibitors of antitumor immune responses, also play an invaluable role in maintaining immune homeostasis. Methods. Peripheral blood was obtained from 42 patients with squannous cell carcinoma of the head and neck (SCCHN) and 24 healthy age-selected donors. The percentages of T-cell subsets and their cytokine profiles expressed in response to ex vivo stimulation were studied by multicolor flow cytometry. Results. Although patients with SCCHN had a lower percentage (p < .05) of circulating CD4+ T cells than healthy donors, CD4+CD25+ regulatory T cells (Treg) were increased in the patients (p < .01). A significant increase in Th1 and Th2 CD4+ T cells was observed in the patients after ex vivo stimulation with phorbol 12-mynstate 13-acetate/ionomycin. The percent of Treg Inversely correlated with that of total CD8+ T cells (p < .05), CD8+IFN-gamma+ (Tc1) cells (p < .05), and CD8+(L-4+ (Tc2) cells (p < .01). There was a highly significant correlation between Tc1 and Tc2 CD8+ T cells (p < .0001) in SCCHN patients but not in controls. Conclusions. Treg are increased in proportion in the circulation of patients with SCCHN. These cells appear to downregulate cytokine expression in both Tc1 and Tc2 subsets of CD8+ effector T cells, which may be responsible for antitumor responses. (c) 2006 Wiley Periodicals, Inc.
引用
收藏
页码:120 / 127
页数:8
相关论文
共 29 条
[1]   Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma [J].
Agarwal, A ;
Rani, M ;
Saha, GK ;
Valarmathi, TM ;
Bahadur, S ;
Mohanti, BK ;
Das, SN .
IMMUNOLOGICAL INVESTIGATIONS, 2003, 32 (1-2) :17-30
[2]   Neuropilin-1: a surface marker of regulatory T cells [J].
Bruder, D ;
Probst-Kepper, M ;
Westendorf, AM ;
Geffers, R ;
Beissert, S ;
Loser, K ;
von Boehmer, H ;
Buer, J ;
Hansen, W .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (03) :623-630
[3]   GENERATION OF POLARIZED ANTIGEN-SPECIFIC CD8 EFFECTOR POPULATIONS - RECIPROCAL ACTION OF INTERLEUKIN (IL)-4 AND IL-12 IN PROMOTING TYPE-2 VERSUS TYPE-1 CYTOKINE PROFILES [J].
CROFT, M ;
CARTER, L ;
SWAIN, SL ;
DUTTON, RW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05) :1715-1728
[4]   Committed memory effector type 2 cytotoxic T (Tc2) cells are ineffective in protective anti-tumor immunity [J].
Do, JS ;
Choi, YH ;
Shin, SH ;
Yi, HK ;
Hwang, PH ;
Nam, SY .
IMMUNOLOGY LETTERS, 2004, 95 (01) :77-84
[5]   Control of immune homeostasis by naturally arising regulatory CD4+ T cells [J].
Gavin, M ;
Rudensky, A .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (06) :690-696
[6]  
Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553
[7]  
Ito N, 1999, CANCER, V85, P2359, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2359::AID-CNCR10>3.3.CO
[8]  
2-1
[9]   Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity [J].
Kemp, RA ;
Ronchese, F .
JOURNAL OF IMMUNOLOGY, 2001, 167 (11) :6497-6502
[10]   Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck [J].
Kim, JW ;
Tsukishiro, T ;
Johnson, JT ;
Whiteside, TL .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :5101-5110